TAUNS LaboratoriesTAUNS Laboratories, Inc.197A東証スタンダード医薬品FY ending Jun 2026, non-consolidated, J-GAAP
TAUNS Laboratories brought in ¥18.4B in revenue.
Out of every ¥100 of sales, about ¥44 is left as operating profit.
Revenue changed +17.6% from the prior year, operating profit +61.7%.
Revenue +17.6% · profit +61.7%, calculated from disclosed figures.
Operating leverage: 3.50× (profit growth ÷ revenue growth)
FY ending Jun 2023 → FY ending Jun 2024
FY ending Jun 2023 → FY ending Jun 2024
For every ¥100 TAUNS Laboratories sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.